Business
Eton Pharmaceuticals Announces Licensing of Rare Disease Product Candidate
Product is currently under review with the FDAPotential approval and launch mid-2026 DEER PARK, Ill., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the licensing of U.S. marketing rights to an ultra-rare disease product candidate. Once approved, the product is expected to be the first and only generic alternative to a
About this update from Eton Pharmaceuticals, Inc.
[{"type":"image","alt":"Eton Pharmaceuticals","displaySize":"","headline":null,"caption":"Eton Pharmaceuticals","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":159,"url":"https://media.zenfs.com/en/globenewswire.com/a0621e3acb49a158aa77f271568b8ffd"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/a2q.GJ3zLE98lva_7jreig--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIyMztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/a0621e3acb49a158aa77f271568b8ffd","width":300,"height":159}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Product is currently under review with the FDA","length":46,"tagName":"p"}]},{"val":[{"type":"text","content":"Potential approval and launch mid-2026","length":38,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":84,"olType":false},{"type":"text","content":"DEER PARK, Ill., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the licensing of U.S. marketing rights to an ultra-rare disease product candidate. Once approved, the product is expected to be the first and only generic alternative to a product used to treat an ultra-rare condition that impacts fewer than 100 patients in the United States.","length":520,"tagName":"p"},{"type":"text","content":"“This bolt-on asset aligns well with our existing commercial infrastructure, adding another potential 2026 product launch to our pipeline and advancing us toward our goal of having one of the largest ultra rare disease product portfolios. We see a compelling opportunity to bring an improved experience to this patient and provider community with our Eton Cares patient support program, as we have successfully demonstrated with our Carglumic Acid, Betaine, and Nitisinone products,” said Sean Brynjelsen, CEO of Eton Pharmaceuticals. “We continue to actively pursue branded, high-value, ultra-rare disease product opportunities, and are excited about our deal pipeline for 2026.”","length":680,"tagName":"p"},{"type":"text","content":"The licensed product is currently under review with the FDA and is expected to be approved and launched in mid-2026. The company will provide additional product details upon approval.","length":183,"tagName":"p"},{"type":"te...